Imidazole propionate and fibrosis in cardiometabolic diseases

IMPACT aims to investigate the role of the microbial metabolite imidazole propionate in promoting fibrosis in heart and liver diseases, potentially leading to new therapeutic strategies.

Subsidie
€ 2.482.678
2023

Projectdetails

Introduction

Fibrosis is a pathological feature caused by excessive extracellular matrix secretion, resulting in scar tissue that causes thickening and loss of tissue mobility, culminating in impaired organ function. It is a common feature of heart failure and non-alcoholic steatohepatitis and an important determinant of morbidity and mortality. However, relatively little is known about the underlying aetiology.

Background

We and others have mapped alterations in the gut microbiota in different cardiometabolic diseases, focusing on the functions performed by the microbiota. IMPACT builds on our work showing that humans with type 2 diabetes have high plasma levels of the microbial metabolite imidazole propionate (ImP) and that ImP impairs insulin signalling through p38gamma.

We also resolved the X-ray crystal structure of urocanate reductase (UrdA), the bacterial enzyme responsible for ImP production. Our recent work showed that ImP is more strongly associated with heart failure and that treatment of mice with ImP promotes both cardiac and liver fibrosis, consistent with studies showing that p38gamma signalling is implicated in fibrosis development.

Objectives

IMPACT will focus on several key objectives:

  1. Clinical Assessments: Use state-of-the-art clinical assessments to determine how circulating levels of ImP correlate with fibrosis in heart and liver.

  2. Kinetics of Fibrosis Induction: Explore the kinetics by which ImP induces fibrosis in mice and how this process is associated with immune cell infiltration and disease progression.

  3. Mechanistic Understanding: Perform similar experiments in mice lacking key target signalling components (e.g., p38gamma), combined with single cell sequencing that will guide us in producing tissue-specific knockouts to elucidate the cellular cross-talk.

  4. UrdA Inhibitors: Generate UrdA inhibitors and test their potential to reduce ImP production in isolated bacteria, complex microbial communities, and colonised mice.

Conclusion

Thus, IMPACT has the potential of generating new therapies to diseases with unmet clinical needs.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.482.678
Totale projectbegroting€ 2.482.678

Tijdlijn

Startdatum1-8-2023
Einddatum31-7-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • GOETEBORGS UNIVERSITETpenvoerder

Land(en)

Sweden

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs

MIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects.

€ 1.933.148
ERC Advanced...

Targeted Re-engineering of the Tumor Matrix to Advance Immunotherapy

This project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment.

€ 2.499.783
ERC Proof of...

Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis

ImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization.

€ 150.000
ERC Starting...

Immune-stromal crosstalk in inflammation and fibrosis: Exploiting the spatiotemporal dynamics of the OSM-OSMR axis in inflammatory bowel disease to develop novel antifibrotic therapies

This project aims to investigate the role of oncostatin-M in immune-stromal interactions driving intestinal fibrosis in IBD, with the goal of identifying biomarkers and potential therapies.

€ 1.499.816
ERC Advanced...

Contextual specification of fibroblast-driven causalities in chronic intestinal inflammation and fibrosis

This project aims to elucidate the role of specific fibroblast subsets in inflammatory bowel disease using single-cell analysis to inform therapeutic strategies and enhance understanding of disease mechanisms.

€ 2.411.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

€ 2.998.878
EIC Transition

Targeting cardiac fibrosis with next generation RNA therapeutics

FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.

€ 2.499.482
EIC Transition

Targeting OGG1 in Idiopathic Pulmonary Fibrosis

The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.

€ 2.499.998